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Background: Children with HIV infection may develop a wide variety of infectious and inflammatory diseases of
the skin. These disorders are often more severe and more difficult to treat than in the immunocompetent child. In
some cases, disorders of the skin or mucous membranes may provide an early clue to the presence of pediatric
HIV infection.
Methods: It is a descriptive cross-sectional study which was conducted at the pediatric infectious disease unit,
department of pediatrics and child health, Tikur Anbesa specialized Hospital. Clinical information was collected
using a questionnaire. The data was analyzed using SSPS 16.0 version. Chi-squared was utilized where appropriate
and a p-value of less than 0.05 was considered statistically significant.
Results: Two hundred seventy HIV infected children were recruited in this study. Out of these females were 51.5%
and males were 48.5%. Most of the children 196/270 (72.6%) were suffering from one or more mucocutanous
disorders. The most prevalent mucocutanous disorders were infectious dermatosis. Overall, mucocutaneous
disorders were more prevalent in advanced stages of HIV disease P < 0.001. Two or more mucocutanous disorders
were found in moderate and sever immunosuppression. Seventy three percent of the HIV-infected children with
mucocutaneous disorders were already on HAART.
Conclusions: The prevalence of mucocutanous disorders is high in HIV infected children. Advanced
immunosuppression is highly associated with a wide spectrum of mucocutanous disorders.Background
Globally, there were a total of 33.2 million people living
with HIV, in 2007, of which 2.5 million (7.5%) were
children under the age of 15 years [1]. Total number of
deaths was 2.1 million, of which 330,000 were children.
It is estimated that more than 90% of children living
with human immunodeficiency virus (HIV) acquired the
virus during pregnancy, birth, or breastfeeding, forms of
HIV transmission that can be prevented [2].
In Ethiopia 44% of the population are children below
15 years. The adult prevalence of HIV is 7.7% in urban* Correspondence: yiche2006@yahoo.com
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reproduction in any medium, provided the orand 0.9% in rural with average population prevalence
2.1%. There are 134,586 children living with HIV/AIDS
and out of whom more than 67,000 are estimated to be
eligible for ART but only 4863 were taking HAART as of
March 2008 [3].
Skin manifestations constitute one of the most com-
mon clinical features in such children and their clinical
pattern and severity is more or less in accordance with
their CD4 counts. Approximately 90% of patients will
develop one or more skin diseases during the course of
their illness and 37% of patients present with skin le-
sions as a marker of HIV infection [4]. Children with
HIV infection are more prone to adverse cutaneous drug
reactions, both to anti-retroviral therapy (ART) and to
other drugs that are given concomitantly for co-morbid
illnesses. Thus, an early recognition of such features isral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Distribution of HIV infected children taking care
and treatment by sex and age (n = 270)
Age groups Males Females Total
n (%) n (%) n (%)
0–5years 20 (15.3) 16 (11.5) 36 (13.3)
5–10 years 45 (34.3) 56 (40.2) 101 (37.4)
10–14years 66 (50.3) 67 (48.2) 133 (49.2)
Total 131 (48.5) 139 (51.5) 270 (100)
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prognosis of HIV infection.
There are no data regarding prevalence and patterns
of mucocutanous disorders among HIV infected children
in Ethiopia. Some data from other nations are very lim-
ited and are mainly from adult cases. Extrapolating from
adult cases is difficult because prevalence and pattern of
mucocutanous lesions varies among children and adults.
Thus, the objective of this study is to determine the pre-
valence and pattern of muocutanous manifestation of
HIV/AIDS among children taking care and treatment in
TikurAnbesa Specialized hospital (TASH).
Methods
Source population
All children who are followed up at the Pediatric Infec-
tious Diseases Clinic, TikurAnbesa Specialized hospital
during the study period.
Study population
All HIV infected children who are taking care and treat-
ment at pediatric Infectious Clinic, Tikur Anbesa Spe-
cialized Hospital during the study time. The sample size
is 196 calculated using the formula z2x p(1-p)/w2, esti-
mated prevalence of 85% (taken from research done in
Tanzania) with 95% CI, and w = 0.05.
All HIV infected children aged up to 14 years, who full
filled the inclusion criteria (all children living with HIV/
AIDS and have been enrolled in care and treatment in
Tikur anbesa hospital) and whose parents/guardians
gave informed consent, were enrolled consecutively until
the required sample size was obtained consecutively.
HIV exposed infant where the infection was not con-
firmed, and children above 14 years of age who being
managed on the adult clinic were excluded from the
study.
Study design
This is a descriptive cross-sectional study which was
conducted at the pediatric infectious disease unit, De-
partment of pediatrics and child health, TikurAnbesa
Specialized .Hospital. In the study, both new and repeat
cases were evaluated thoroughly for occurrence of muco-
cutanous lesions by a senior pediatric (YE) resident in col-
laboration with dermatologist. Data was collected using
standard pretested questionnaire.
Clinical staging was done according to the WHO pedia-
tric staging of HIV/AIDS. While immunologic classifi-
cation was done according to the CDC immunologic
classification for HIV infected infants and children.
Dermatological examination was done in daylight.
Diagnoses of most dermatoses were done clinically.
Where necessary, appropriate laboratory tests like
KOH from skin scraps and gram stain, culture andsensitivity from pus swabs were performed to con-
firm the diagnosis.
Data collection
All subjects had a complete history and physical examin-
ation and necessary diagnostic procedures from skin
were done to confirm the diagnosis. Trained residents,
nurses and data clerks working in PIDC were engaged
for data collection and data entry.
Data analysis
Statistical analysis was done using the Statistical Package
for Social Sciences (SPSS) program version 16.0. Chi-
squared test was used for categorical variables. A p-value
of less than 0.05 was considered statistically significant.
Ethical clearance for this study was obtained from in-
stitutional research review board (IRB) of the college
of health sciences. Anything that breaks the anony-
mity of the individual was avoided including name.
Verbal assent from the child, and consent from the
guardian or parent was obtained and confidentiality
has been assured.
Results
A total of 270 HIV infected children were recruited into
the study. There were 48.5% (131/270) males and 51.5%
(139/270) females. The age ranged from 2 months to
14 years (mean age 9.3 years with 3.5 ± SD). All were
from Addis Ababa.
Over all 72.6% (196/270) had mucocutanous disorders.
Almost males and females were equally infected with
one or more mucocutanous lesions (72.5% and 72.6%)
respectively. The prevalence of mucocutanous disorders
under 5 years age was 77.7%, while for those greater
than 5 years was 71.7% (p value = 0.68) (Table 1).
There was a wide variety of mucocutanous disorder as
shown in Table 2. Infectious dermatosis accounted for
the majority of mucocutanous disorders (82.6%) while
noninfectious/inflammatory dermatosis accounted for
44.8% (Table 3). Many children had multiple skin condi-
tions and were therefore counted more than once in cer-
tain situations.
Superficial fungal infections were the commonest con-
ditions present in 51.8% followed by PPE in 44.2% of the
Table 2 Mucocutanous disorders in HIV infected children
attending PIDC, Tikur Anbesa Specialized Hospital
(n = 196)
Mucocutanous disorder N %
Noninfectious inflammatory dermatosis 88 44.8
Papular pruritic rash (PPE) 60 30.6
Seborrhic dermatitis 15 7.7
Atopic dermatitis 6 3
Drug rash 6 3
Erythema nodosum 1 0.5
Infectious dermatitis 162 82.6
Superficial fungal infection 102 51.8
Tinea capitis 55 28
Tinea corporis 34 17.3
Tineaungum 7 3.5
Pityriasisversicolor 2 1
Oral thrush 4 2
Viral infections 38 19.3
Molluscum contagiosum 27 13.8
Herpes simplex 4 2
Herpes zoster 3 1.5
Chicken pox 3 1,5
Measles 1 0.5
Bacterial infections 20 10.2
Impetigo 18 9.2
Folliculitis 2 1
Infestation (scabies) 2 1
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was tinea capitis, occurring in 28% while the least fre-
quent was tinea (pityriasis) versicolor found in only two
children (1%). Viral and bacterial infection occurred in
19.3% and 10.2% of patients respectively. Among nonin-
fectious dermatosis, PPE was the commonest (30.6%)
followed by seborrhic dermatitis (7.7%) and the least
frequent non infectious mucocutanous disorder was
erythema nodosum. The commonest bacterial skin in-
fection was impetigooccurring in 9.2%.
Molluscum contagiosum found in 13.8%, was the com-
monest viral infection, while measles present in only one
child. Six children had drug rash induced by Nevirapine.
There was no neoplasm encountered in this study.Table 3 Distribution of mucocutanous disorder in HIV infecte
Less than 5 years 5–10 y
Mucocutanous disorder n=28 (%) n=71
Non infectious dermatosis 10 (35.7) 33 (46
Infectious dermatosis 27 (96.4) 56 (78The prevalence of mucocutaneous disorders was high-
est in the advanced paediatric WHO stages III (76.9%)
and IV (88.8%) and relatively lower in stage II andI
61.2% and 55.5% respectively (p < 0.001). Similarly chil-
dren with severe immunosuppression by CDC criteria
had the highest prevalence of mucocutaneous disorders
(100%), followed by those with moderate immunosup-
pression (70%) while children with no evidence of im-
munosuppression had the lowest (48.3%) prevalence
(p < 0.000). The mean CD4 count was low in children
who have mucocutanous lesion (456 ± 285 sd) while those
who has nomucocutanous disorder was (646 ± 270 sd)
with p value = 0.026 (Table 4).
Two and more mucocutanous lesions in one child
were common with sever immunosuppression (34.8%)
followed by moderate immunosuppression (30%) while
children with no evidence of immunosuppression had
lowest (22%) with p value = 0.00.
From 196 children who had mucocutanous disorders
141(72.6%) were on HAART according to Ethiopian
HIV/AIDS treatment guideline. Of these 32.6% had been
on HAART for more than 12 months, while 20% and
19.4% were on HAART for less than 6 months and bet-
ween 6 months and 12 months respectively.
Discussion
In this this study, 72.6% of HIV/AIDS pediatric patients
attending care and treatment inTikurAnbesa Hospital
had a wide range of mucocutaneous disorders. High
prevalence of skin diseases among HIV infected chil-
dren similar to this study has been reported in Tanzania
(85%) [5], Thailand (83%) [6] and Cameroon (68.8%) [7].
Other studies showed different results [8] the difference
may be due to geographic variation and quality of care.
A study by Luminus et al. showed that children less than
five years of age are the least affected than the older
ones, [9], but in our study there is no significant diffe-
rence among younger and older children similar to that
of Tanzanian study [5].
According to a study in Thailand the prevalence of
mucocutanous disorder in sever, moderate and no evi-
dence of immunosuppression was 62%, 43% and 20% re-
spectively [10] and similar study in Tanzania showed
97%, 84.5% and 71% respectively. In this study, the
prevalence of mucocutaneous disorders among chil-
dren with severe, moderately severe and no evidenced children by age
Age groups
ears 10–14 years Total p value
(%) n=97 (%) n=196 (%)
.4) 45 (46.4) 88 (44.8) 0.62
.8) 79 (81.4) 162 (82.6) 0.32
Table 4 Prevalence of mucocutanous disorder among HIV infected children by WHO and CDC disease progression
(n = 270)
Mucocutanous disorder Mucocutanous disorder Total p value
Present n=196 Absent n=74 n=270
WHO pediatric stage
I 5 (55.5) 4 (44.5) 9 (3.3)
II 63 (61.2) 40 (38.8) 103 (38.2) < 0.001
III 80 (78) 24 (22) 104 (38.5)
IV 48 (88.9) 6 (11.1) 54 (20)
Immunosuppression level by CDC
No evidence (category I) 44 (48.3) 47 (51.7) 91 (33.7)
Moderate (category II) 63 (70) 27 (30) 90 (33.3) 0.000
Sever (category III) 89 (100) 0 (0) 89 (33)
Mean cd4 456 (±285sd) 646 (±270) 0.026
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spectively and the differences were statistically signi-
ficant (p < 0.001). Most children with moderate and
sever immunosuppression have two and more muco-
cutanous disorder [10]. Similarly our study showed two
and more skin disorders were more common in advanced
immunosuppression.
All of the above studies including ours indicate that
the risk of acquiring mucocutaneous disorders for HIV
infected children rises as the level of immunosuppres-
sion advance. In this study Infectious dermatosis are
the most frequent cause of mucocutaneous disorders
among HIV infected children like other studies [5]. In
this study, the most common infectious dermatosis
was superficial fungal infections and the most com-
mon non infectious dermatosis was prurritic popular
eruption (PPE) similar to another study [5]. The in-
creased incidence of skin infections is attributed to
the depletion of the Langerhan's cells responsible for
the mucocutaneous immunological system.non infec-
tious dermatosis also become prevalent whenthere is
immunosuppression [5,7].
Patients with HIV disease are particularly prone to
hypersensitivity drug eruptions [11]. In our study 6 chil-
dren (3%) had moderate to severe drug rash secondary
to nevirapine. kaposis sarcoma which is common cutae-
nous neoplasm in HIV infected adults is rare in children.
In Tanzania study only one child was found to have
kaposis sarcoma [5,11]. In this study there was no a case
of kaposis sarcoma indicating cutanous neoplasms are
rare in children.
Study done by Sibhatu B et al. on adherence to
HAART in pediatric patients in Addis Ababa at different
hospitals including Tikur Anbesa (Black Lion) Hospital
was 86% which is low compared to other setups [12].
Some studies indicate that HAART decrease the preva-
lence of mucocutanous disorders especially viral infectionsin HIV infected individuals [13]. But in our study and
Tanzanian study [5], there was no significant difference in
the prevalence of mucocutanous disorder among children
on HAART and pre-ART care. For ART to have a signifi-
cant effect on mucocutaneous disorders, it needs to be ad-
ministered for a longer period of time and patients should
be adherent to treatment. In a study by Donic I. et al., it
was found that the use of ART for about two years re-
duced significantly the presence of oral candidosis and
seborrheic dermatitis [14].
This study is cross sectional which does not allow us
to assess treatment response and course of mucocuta-
nous disorder and to see effect of HAART.
Conclusions
From this study it can be concluded that there is a high
prevalence of mucocutanous disorder in HIV infected
children. Most of the mucocutanous disorders were se-
condary to infectious causes. Children with advanced
immunosuppression are suffering from a wide spectrum
of mucocutanous disorders. Thus it is recommended
that mucocuatnous disorders being so common among
HIV infected children thorough evaluation should be
done in HIV care and treatment centers to address these
problems.
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